Testosterone levels
Related entities
Findings (27)
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null
None
nullTestosterone levels were significantly lower compared to baseline in the metformin group at 3 months but not at 6 months, indicating a transient androgen-lowering effect that did not persist.
Effect: null